Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Should You Sell?

Genmab A/S (OTCMKTS:GNMSF) gapped down before the market opened on Tuesday . The stock had previously closed at $274.75, but opened at $252.70. Genmab A/S shares last traded at $252.70, with a volume of 47 shares.

Genmab A/S Stock Down 0.1%

The stock has a market cap of $16.44 billion, a P/E ratio of 17.25 and a beta of 0.92. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. The firm’s fifty day moving average is $298.38 and its 200 day moving average is $306.60.

Genmab A/S (OTCMKTS:GNMSF) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.